Dissecting the YAP-TEAD–PPARα Axis in Hepatic Regeneration: Insights from WY-14643–Driven Mouse Models

Study Background and Research Question

Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor with established roles in lipid metabolism regulation, inflammation, and insulin sensitivity enhancement. While pharmacological activation of PPARα—using potent agents such as WY-14643 (Pirinixic Acid)—has been extensively studied in metabolic disorder research, the mechanisms by which PPARα influences liver growth and regeneration are less clearly defined. The reference study sought to resolve a critical gap: What molecular effectors mediate the hepatomegaly and liver regenerative responses triggered by PPARα activation in vivo (reference_paper)?

Key Innovation from the Reference Study

The study demonstrates that the transcriptional co-activator YAP (Yes-associated protein), in complex with TEAD family transcription factors, is essential for PPARα-induced hepatomegaly and liver regeneration. This work provides the first in vivo evidence that YAP-TEAD signaling is a downstream mediator of PPARα activation, establishing a mechanistic bridge between metabolic receptor pharmacology and regenerative pathways (reference_paper).

Methods and Experimental Design Insights

The investigators used a robust genetic and pharmacological toolkit in mice:

• Mouse models: Wild-type C57BL/6, Pparafl/fl, hepatocyte-specific Pparα knockout (PparaΔHep), Yapfl/fl, and hepatocyte-specific Yap knockout (Yap∆Hep) mice.
• Pharmacological treatment: Intraperitoneal administration of WY-14643 (100 mg/kg/day) or vehicle (corn oil) for 10 days to activate PPARα signaling.
• Liver regeneration paradigm: Partial hepatectomy (PHx) followed by WY-14643 or vehicle treatment, with tissue and serum collection at defined time points (2 and 5 days post-surgery).
• YAP-TEAD inhibition: Verteporfin (a YAP-TEAD inhibitor) and AAV-mediated YAP knockdown were used to selectively disrupt YAP signaling.
• Readouts: Histological (H&E, β-catenin, KI67 staining), morphometric (hepatocyte size, proliferation index), and biochemical (ALT, AST, ALP, ALB, TBA, TBIL) assays, as well as quantitative RT-PCR for gene expression profiling.

This multifaceted approach allowed precise dissection of the sequential roles of PPARα and YAP in hepatic growth and regeneration (reference_paper).

Protocol Parameters

• in vivo PPARα activation | 100 mg/kg/day WY-14643, IP injection | mouse hepatomegaly/liver regeneration | Standard dose for robust PPARα pathway activation in murine models | reference_paper
• YAP-TEAD inhibition | 100 mg/kg/day verteporfin, IP injection | YAP pathway interrogation | Selectively blocks YAP-TEAD complex to assess downstream effects | reference_paper
• Partial hepatectomy | ~2/3 liver resection | Liver regenerative capacity | Gold-standard model for studying hepatic regeneration | reference_paper
• Histological assessment | H&E, β-catenin, KI67 staining | Cellular proliferation and morphology | Enables quantification of hepatocyte size and proliferative index | reference_paper
• Gene expression quantification | qRT-PCR (∆∆Ct) | Pathway target validation | Sensitive detection of transcriptomic changes | reference_paper
• WY-14643 solution preparation | Dissolve in DMSO or ethanol; warming/ultrasonication recommended | For insoluble in water compounds | Ensures full solubilization for accurate dosing | workflow_recommendation

Core Findings and Why They Matter

The findings can be summarized into three major advances:

• PPARα activation triggers hepatomegaly and accelerates liver regeneration. Mice treated with WY-14643 exhibited significant increases in liver mass and hepatocyte proliferation, both in the native and post-hepatectomy setting (reference_paper).
• Both PPARα and YAP are essential for this proliferative response. Genetic ablation of Ppara in hepatocytes (PparaΔHep) abolished WY-14643–induced liver growth, confirming the specificity of the agonist’s action (reference_paper). Similarly, hepatocyte-specific Yap knockout (Yap∆Hep) or pharmacological YAP-TEAD inhibition with verteporfin blocked the hepatomegaly and regenerative response, positioning YAP-TEAD as a necessary effector downstream of PPARα.
• Molecular crosstalk underpins PPARα–YAP-TEAD signaling. The study’s gene expression and histological data reveal that WY-14643–induced activation of PPARα leads to upregulation of YAP target genes associated with cell growth and proliferation (reference_paper).

These results integrate metabolic regulation (via PPARα) with regenerative biology (via YAP-TEAD), highlighting the dual utility of selective PPARα agonists in both metabolic and regenerative research domains.

Comparison with Existing Internal Articles

Recent internal articles have extensively discussed the application of WY-14643 (Pirinixic Acid) as a selective PPARα agonist in metabolic disorder research, particularly in contexts involving lipid metabolism regulation, inflammatory signaling, and insulin sensitivity enhancement (internal_article_1, internal_article_3). However, this new reference work extends the significance of WY-14643 by demonstrating its application in liver regeneration and organ growth, not just metabolic endpoints. While previous articles focused on anti-inflammatory agent properties in endothelial cells and metabolic disease models, the current study uniquely positions the PPARα–YAP-TEAD axis as a critical regulatory node in hepatic regeneration. This opens new investigative pathways beyond conventional metabolic disease models (internal_article_2).

Limitations and Transferability

Despite its mechanistic depth, the study’s findings are primarily derived from murine models using high-dose intraperitoneal administration of WY-14643. While the genetic models (PparaΔHep, Yap∆Hep) provide rigorous specificity, the transferability of these results to human liver biology remains to be established. Additionally, the pharmacokinetics and tissue distribution of WY-14643 in these models may not fully recapitulate clinical or translational contexts. Researchers should be cautious in extrapolating the regenerative effects of PPARα agonists to other organs or disease states without further validation. The study does not address potential off-target or long-term effects of sustained PPARα–YAP activation in vivo (reference_paper).

Research Support Resources

To facilitate mechanistic studies of PPARα in metabolic and regenerative contexts, researchers can leverage commercially available, well-characterized reagents. For example, WY-14643 (Pirinixic Acid) (SKU A4305, APExBIO) offers a validated tool for probing selective PPARα signaling in vivo and in vitro workflows. The compound’s solubility and storage recommendations, as well as its established in vivo activity, are detailed in both the product dossier and internal validation articles (source: internal_article_1). For optimal results, researchers should prepare solutions in DMSO or ethanol with warming/ultrasonication, and adhere to recommended storage conditions.

---

Reference: Wang S, Fan S, Gao Y, et al. YAP-TEAD mediates peroxisome proliferator-activated receptor α induced hepatomegaly and liver regeneration in mice. Manuscript Ref. No.: HEP-21-0169.